|

Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision

RECRUITINGSponsored by Elucent Medical
Actively Recruiting
SponsorElucent Medical
Started2024-08-07
Est. completion2026-02-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site

Summary

Observational study. The purpose of this study is to evaluate the use of real-time surgical navigation for the localization and surgical removal of soft tissue tumors. The goal is to collect information about the efficiency and effectiveness of the EnVisio Surgical Navigation for intraoperative guidance to obtain negative margin on initial specimen. Prospective Patient Study: 200 consecutive patients

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Patient has image identifiable lesion.
* Patient has selected breast conservation therapy IE: lumpectomy +/-radiation therapy, +/- chemotherapy +/- hormonal or targeted therapies. Neoadjuvant chemotherapy is not an exclusion criterion.
* Patient will be undergoing target tissue localization with the SmartClip
* Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio ® Navigation System.
* Patient must be age \> or = 18 years.
* Patients unable to provide consent to surgery must have authorized representative provide consent.

Exclusion Criteria:

* Patients undergoing mastectomy for resection of the targeted lesion.
* Patient is localized with an alternative method.
* Patient that are pregnant.

Conditions3

Breast CancerCancerTumors, Breast

Locations1 site

Advent Winter Garden
Winter Garden, Florida, 34787
Jason A Boardman, MD352-243-2622jaboardmanmd@hotmail.com

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.